Literature DB >> 23509970

New hope for multiple sclerosis patients.

Craig W Lindsley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23509970      PMCID： PMC3605809          DOI： 10.1021/cn400059g

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN： 1948-7193            Impact factor:   4.418


× No keyword cloud information.
  4 in total

1.  Oral therapy for multiple sclerosis--sea change or incremental step?

Authors:  William M Carroll
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

Review 2.  Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  D S Goodin; B A Cohen; P O'Connor; L Kappos; J C Stevens
Journal:  Neurology       Date:  2008-09-02       Impact factor: 9.910

3.  Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Authors:  Jeffrey A Cohen; Alasdair J Coles; Douglas L Arnold; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Elizabeth Fisher; Vesna V Brinar; Gavin Giovannoni; Miroslav Stojanovic; Bella I Ertik; Stephen L Lake; David H Margolin; Michael A Panzara; D Alastair S Compston
Journal:  Lancet       Date:  2012-11-01       Impact factor: 79.321

Review 4.  Primary-progressive multiple sclerosis.

Authors:  David H Miller; Siobhan M Leary
Journal:  Lancet Neurol       Date:  2007-10       Impact factor: 44.182
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.